Q22P (p.Gln22Pro) variant of KRAS (GTPase KRas)
Q22P (p.Gln22Pro) in KRAS (GTPase KRas) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as uncertain significance in the context of Prostate cancer, hereditary, 1. The available variant effect predictions contribute to a CATVariant prioritization score of 0.77 / 1. The record also includes experimental measurements, published literature, and structural context.
Q22P (p.Gln22Pro) variant details
- p.Gln22Pro
- rs727503110
- ClinGen CA384157368
- ClinVar RCV002292312
- Uncertain significance
- Prostate cancer, hereditary, 1
- Missense
- Variant Prioritization Score for Impact Estimate 0.767
- AlphaMissense 0.98
- MetaLR 0.72
- MetaSVM 0.61
- PolyPhen-2 1.00
- SIFT 0.00
- EVE 0.74
- ClinVar: Uncertain significance (Prostate cancer, hereditary, 1)
- EBI: Variant of uncertain significance (in NS3)
- UniProt: Uncertain significance (in NS3)
- Structural context available
- abundance fitness from abundancePCA of KRAS block1: score -0.699
- Cited in: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic… (PMID 25394175)
- Cited in: Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. (PMID 31829902)